These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

811 related items for PubMed ID: 26991643

  • 21. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor.
    O'Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P, Höfner K.
    BJU Int; 2003 Aug; 92(3):262-6. PubMed ID: 12887480
    [Abstract] [Full Text] [Related]

  • 22. Urodynamic effects of dutasteride add-on therapy to alpha-adrenergic antagonist for patients with benign prostatic enlargement: prospective pressure-flow study.
    Wada N, Kita M, Hashizume K, Matsumoto S, Kakizaki H.
    Neurourol Urodyn; 2013 Nov; 32(8):1123-7. PubMed ID: 23861329
    [Abstract] [Full Text] [Related]

  • 23. Dutasteride add-on therapy reduces detrusor mass in patients with benign prostatic enlargement not satisfied with alpha-adrenergic antagonist monotherapy: A single center prospective study.
    De Nunzio C, Brassetti A, Proietti F, Gacci M, Serni S, Esperto F, Tubaro A.
    Neurourol Urodyn; 2017 Nov; 36(8):2096-2100. PubMed ID: 28257560
    [Abstract] [Full Text] [Related]

  • 24. Clinical Effects of Oral Supplementation of Gamma-Cyclodextrin Curcumin Complex in Male Patients with Moderate-To-Severe Benign Prostatic Hyperplasia-Related Lower Urinary Tract Symptoms.
    Crocerossa F, Cantiello F, Bagalá L, Sicoli F, Carbonara U, Manfredi C, Falagario U, Veccia A, Pandolfo SD, Napolitano L, Ferro M, Di Dio M, Mondaini N, Damiano R.
    Urol Int; 2023 Nov; 107(10-12):924-934. PubMed ID: 37939691
    [Abstract] [Full Text] [Related]

  • 25. Effect of tamsulosin hydrochloride on lower urinary tract symptoms and quality of life in patients with benign prostatic hyperplasia. Evaluation using bother score.
    Yoshida M, Sugiyama Y, Masunaga K, Maeda Y, Satoji Y, Nagata T, Inadome A.
    Drugs Today (Barc); 2007 Jun; 43 Suppl B():1-7. PubMed ID: 17612712
    [Abstract] [Full Text] [Related]

  • 26. Triple Therapy with Tamsulosin, Dutasteride, and Imidafenacin for Benign Prostatic Hyperplasia in Patients with Overactive Bladder Symptoms Refractory to Tamsulosin: Subgroup Analyses of the DIrecT Study.
    Yamanishi T, Asakura H, Seki N, Tokunaga S.
    Urol Int; 2021 Jun; 105(9-10):817-825. PubMed ID: 33690238
    [Abstract] [Full Text] [Related]

  • 27. Efficacy of Additional Dutasteride on Lower Urinary Tract Symptoms in Patients with Alpha-1 Blocker-Resistant Benign Prostatic Hyperplasia.
    Sengiku A, Miyazaki Y, Sawazaki H, Takahashi T, Ogura K.
    Low Urin Tract Symptoms; 2013 Sep; 5(3):159-63. PubMed ID: 26663453
    [Abstract] [Full Text] [Related]

  • 28. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
    Kaplan SA, Chung DE, Lee RK, Scofield S, Te AE.
    Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
    [Abstract] [Full Text] [Related]

  • 29. Decreased urinary nerve growth factor reflects prostatic volume reduction and relief of outlet obstruction in patients with benign prostatic enlargement treated with dutasteride.
    Wada N, Matsumoto S, Kita M, Hashizume K, Kakizaki H.
    Int J Urol; 2014 Dec; 21(12):1258-62. PubMed ID: 25039474
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis.
    Kim HJ, Sun HY, Choi H, Park JY, Bae JH, Doo SW, Yang WJ, Song YS, Ko YM, Kim JH.
    PLoS One; 2017 Dec; 12(1):e0169248. PubMed ID: 28072862
    [Abstract] [Full Text] [Related]

  • 31. Prostatic arterial embolization for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia: a comparative study of medium- and large-volume prostates.
    Wang M, Guo L, Duan F, Yuan K, Zhang G, Li K, Yan J, Wang Y, Kang H.
    BJU Int; 2016 Jan; 117(1):155-64. PubMed ID: 25851432
    [Abstract] [Full Text] [Related]

  • 32. What are the predicting factors for the therapeutic effects of dutasteride in male patients with lower urinary tract symptoms? Investigation using a urodynamic study.
    Matsukawa Y, Kato M, Funahashi Y, Majima T, Yamamoto T, Gotoh M.
    Neurourol Urodyn; 2017 Sep; 36(7):1809-1815. PubMed ID: 28102554
    [Abstract] [Full Text] [Related]

  • 33. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
    Pinto F, Racioppi M, Sacco E, Totaro A, Brescia A, Volpe A, Gardi M, Bassi PF.
    Arch Ital Urol Androl; 2009 Mar; 81(1):1-8. PubMed ID: 19499750
    [Abstract] [Full Text] [Related]

  • 34. Early effect of dutasteride added to alpha-1 blocker therapy for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Araki K, Naya Y, Inahara M, Suzuki F, Ota S, Tsuji H, Mikami K, Yanagisawa M, Awa Y, Suzuki H.
    Int J Urol; 2014 Aug; 21(8):815-9. PubMed ID: 24735081
    [Abstract] [Full Text] [Related]

  • 35. Comparison of Silodosin Monotherapy vs Silodosin With Tadalafil Add-on Therapy in Patients With Benign Prostatic Hyperplasia.
    Yoshida T, Kinoshita H, Shimada S, Taguchi M, Matsuda T.
    Urology; 2017 Aug; 106():153-159. PubMed ID: 28431996
    [Abstract] [Full Text] [Related]

  • 36. Effect of preoperative detrusor underactivity on long-term surgical outcomes of photovaporization and holmium laser enucleation in men with benign prostatic hyperplasia: a lesson from 5-year serial follow-up data.
    Cho MC, Yoo S, Park J, Cho SY, Son H, Oh SJ, Paick JS.
    BJU Int; 2019 May; 123(5A):E34-E42. PubMed ID: 30582661
    [Abstract] [Full Text] [Related]

  • 37. [The Clinical Course of α1 Blocker Discontinuation in Patients with LUTS/BPH Receiving Combination Therapy of Dutasteride and α1 Blocker].
    Watanabe M, Wada N, Kita M, Hori J, Tamaki G, Kakizaki H.
    Hinyokika Kiyo; 2020 Sep; 66(9):289-292. PubMed ID: 32993272
    [Abstract] [Full Text] [Related]

  • 38. A 52-week multicenter randomized controlled study of the efficacy and safety of add-on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study).
    Yamanishi T, Asakura H, Seki N, Tokunaga S.
    Low Urin Tract Symptoms; 2019 May; 11(3):115-121. PubMed ID: 30358116
    [Abstract] [Full Text] [Related]

  • 39. Transitional Zone Index as a Predictor of the Efficacy of α-Blocker and 5α-Reductase Inhibitor Combination Therapy in Korean Patients with Benign Prostatic Hyperplasia.
    Choi JD, Kim JH, Ahn SH.
    Urol Int; 2016 May; 96(4):406-12. PubMed ID: 26824527
    [Abstract] [Full Text] [Related]

  • 40. Effects of dutasteride on serum free-testosterone and clinical significance of testosterone changes.
    Enatsu N, Miyake H, Haraguchi T, Chiba K, Fujisawa M.
    Andrologia; 2016 Dec; 48(10):1195-1201. PubMed ID: 26952737
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 41.